EDNRA and pulmonary arterial hypertension: It has been shown to improve both clinical and hemodynamic parameters in patients with advanced disease on ART.[19–21] The ET-A selective ERA Ambrisentan was extensively studied in 3 sequential trials of PAH (overall N = 393, 11 of whom had HIV-associated PAH) and was found to similarly improve pulmonary hemodynamics and delay clinical progression.[36–38] Head-to-head studies of non-selective versus selective blockade of ET-1 receptors are needed to establish the first-line ERA in HIV-associated PAH.